RT Journal Article
T1 Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.
A1 Driessen, M T
A1 Whalen, J
A1 Buguth, B Seewoodharry
A1 Vallejo-Aparicio, L A
A1 Naya, I P
A1 Asukai, Y
A1 Alcázar-Navarrete, B
A1 Miravitlles, M
A1 García-Río, F
A1 Risebrough, N A
AB Following publication of the original article [1], we have been notified of the below corrections to the 5th paragraph in the Discussion section.
YR 2019
FD 2019-01-28
LK http://hdl.handle.net/10668/13475
UL http://hdl.handle.net/10668/13475
LA en
DS RISalud
RD Apr 20, 2025